The use of “TIL signatures” as biomarkers to predict response to immune checkpoint inhibitors (i.e., anti-PD-1/PDL1, CTLA4) hold the potential to augment the efficacy of lung cancer therapy and, ultimately, increase lung cancer patients’ overall survival. The gene discussed is CTLA4; the disease is lung carcinoma.